Arrthymia Sinus tachycardia Ventricular tachycardia Atrial fibrillation Shanghai Institute of Cardiovascular Diseases
Sinus tachycardia Ventricular tachycardia Atrial fibrillation
Radionuclide Imaging e Provides quantification of reduced ejection fraction in either or both ventricles ◆ May be useful to exclude 81/31 ischemic heart failure ◇ Not always necessary FRoN 份 oΦoo REST HIBI SPEC Shanghai Institute of Cardiovascular Diseases
Provides quantification of reduced ejection fraction in either or both ventricles May be useful to exclude ischemic heart failure Not always necessary
Magnetic Resonance Imaging Likely to become increasingly useful to ARVD/C evaluate specific cardiomyopathies when suspected Endocardial fibroelastosis Myocarditis Amyloidosis Shanghai Institute of Cardiovascular Diseases
Likely to become increasingly useful to evaluate specific cardiomyopathies when suspected ARVD/C Endocardial fibroelastosis Myocarditis Amyloidosis
Biomarkers Differation Thyroid function Antinuclear antibody °cTnT,cTnl Prognosis bNP proBNP Further Renal function treatment. Serum electrolytes Shanghai Institute of Cardiovascular Diseases
• Thyroid function • Antinuclear antibody Differation • cTnT, cTnI • BNP, proBNP Prognosis • Renal function • Serum electrolytes Further treatment
Natriuretic Peptides High levels of natriuretic peptides identify those at greatest risk of future serious cardiovascular events Includin ng death There is also recent evidence that adjusting heart failure therapy in order to reduce natriuretic peptides levels in individual patients may improve outcome Q ESC Guidelines on Diagnosis and Treatment of CHF